National Organization for Rare Disorders, Inc.
It is possible that the main title of the report Depersonalization Disorder is not the name you expected. Please check the synonyms listing to find the alternate name(s) and disorder subdivision(s) covered by this report.
Related Disorders List
Information on the following diseases can be found in the Related Disorders section of this report:
- Panic-Anxiety Syndrome (Panic Disorder)
Depersonalization disorder is a psychiatric disorder affecting emotions and behavior. It is characterized by an alteration in how an affected individual perceives or experiences his or her unique sense of self. The usual sense of one's own reality is temporarily lost or changed. A feeling of detachment from, or being an outside observer of, one's mental processes or body occurs such as the sensation of being in a dream.
Depersonalization disorder is characterized by persistent or recurring episodes of the loss of the sense of self (depersonalization). The symptoms of depersonalization disorder are sufficient enough to cause marked distress or impairment in social, occupational, or other important areas of life. The usual sense of one's self or reality is temporarily changed or lost. A feeling of detachment from, or being an outside observer of, one's mental processes or body occurs. The affected individual may feel as if he/she is in a dream. Affected individuals may experience various types of lack of sensory stimulation (sensory anesthesia) and a sensation of not being in complete control of one's actions, including speech. This condition may not occur during the course of another mental disorder or be the effects of a substance or general medical condition.
Depersonalization disorder usually starts during adolescence or early adulthood. The disorder is usually chronic with periods of remission. More severe manifestations may be aggravated by mild anxiety or depression. The disorder usually disappears gradually.
The exact cause of depersonalization disorder is not known. A traumatic event such as military combat, a car accident, or being a victim of a violent crime may trigger an episode of depersonalization disorder. Substance use may cause depersonalization episodes, but not the disorder.
Depersonalization disorder is believed to affect women twice as much as men. The disorder most commonly affects individuals between the ages of 15 and 30. It is rarely seen in those over the age of 40.
The following disorders may be associated with Depersonalization Disorder as secondary characteristics. They are not necessary for a differential diagnosis:
Panic-Anxiety Syndrome (Panic Disorder) is characterized by recurrent attacks of intense fear or discomfort beginning without warning. These attacks typically begin with the sudden onset of intense apprehension, fear, terror, or discomfort without apparent cause. At least four of the following symptoms may occur: shortness of breath (dyspnea) or smothering sensations; dizziness, unsteady feelings, or faintness; choking; palpitations or accelerated heart rate; trembling or shaking; sweating; nausea or abdominal distress; loss of one's sense of self (depersonalization) or feelings of unreality; numbness or tingling sensations (paresthesias); flushes (hot flashes) or chills; chest pain or discomfort; etc. (For more information, choose "Panic-Anxiety Syndrome" as your search term in the Rare Disease Database.)
Agoraphobia is the fear of being in places or situations from which escape might be difficult or embarrassing, or in which help might not be available in the event of a panic attack. As a result of this intense fear, people with Agoraphobia do not leave their home. Common situations that may trigger an agoraphobic attack include being outside the home alone, being in a crowd or standing in line, being on a bridge, or traveling in a bus, train, or car.
The diagnosis of depersonalization disorder can be suspected after a complete physical examination and laboratory tests have ruled out any substance or geneal medical condition. A complete psychiatric evaluation should also be conducted.
Treatment of depersonalization disorder involves psychotherapy. The antidepressant drug desipramine may be beneficial. The drugs dextroamphetamines and amobarbital (Amytal) combined with chlorpromazine (Thorazine) may be beneficial if anxiety is experienced. Other treatment is symptomatic and supportive.
Information on current clinical trials is posted on the Internet at www.clinicaltrials.gov. All studies receiving U.S. government funding, and some supported by private industry, are posted on this government website.
For information about clinical trials being conducted at the National Institutes of Health (NIH) in Bethesda, MD, contact the NIH Patient Recruitment Office:
Tollfree: (800) 411-1222
TTY: (866) 411-1010
For information about clinical trials sponsored by private sources, contact:
A study to determine the effects of fluoxetine on patients with depersonalization disorder was recently (2005) completed. This study was sponsored by the National Institute of Mental Health and Mount Sinai School of Medicine. Further information is available on the www.clinicaltrials.gov web site.
Comprehensive Textbook of Psychiatry/V, 5th Ed.: Harold I. Kaplan and Benjamin J. Sadock, Editors; Williams & Wilkins, 1989. Pp. 1038-43.
Diagnostic and Statistical Manual of Mental Disorders: DSM IV, 4th Ed.: A. Frances et. al., Editors; American Psychiatric Association, 1994. Pp. 488-90.
Treatments of Psychiatric Disorders, 2nd Ed.: Glen O. Gabbard, M.D., Editor; American Psychiatric Association, 1995. Pp. 1634-53.
Desipramine: A Possible Treatment for Depersonalization Disorder. R. Noyes, Jr. et al.; Canadian Journal Psychiatry (Dec 1987; 32(9)). Pp. 782-84.
Depersonalization in a Nonclinical Population. D. Trueman; Journal Psychol (Jan 1984; 116 (1st half)). Pp. 107-12.
Depersonalization and Agoraphobia Associated with Marijuana Use. C. Moran; British Journal Med Psychol (Jun 1986; 59(pt 2)). Pp. 187-96.
Feelings Unreal: 30 Cases of DSM-III-R Depersonalization Disorder. D. Simeon et al.; Am J Psychiatry (Aug 1997; 154(8)). Pp. 1107-13.
Depersonalization Disorder and Self-Injurious Behavior. D. Simeon et al.; J Clin Psychiatry (1995; 56(suppl 4)). Pp. 36-39.
FROM THE INTERNET
eMedicine - Dissociative Disorders : Article by Idan Sharon, MD
National Mental Health Consumers' Self-Help Clearinghouse
1211 Chestnut Street
Philadelphia, PA 19107-6312
Mental Health America
2000 N. Beauregard Street, 6th Floor
Alexandria, VA 22314-2971
National Alliance on Mental Illness
3803 N. Fairfax Drive
Arlington, VA 22203-
NIH/National Institute of Mental Health
Health Science Writing, Press and Dissemination Branch
6001 Executive Boulevard
Room 8184, MSC 9663
Bethesda, MD 20892-9663
Genetic and Rare Diseases (GARD) Information Center
PO Box 8126
Gaithersburg, MD 20898-8126
For a Complete Report
This is an abstract of a report from the National Organization for Rare Disorders, Inc.® (NORD). Cigna members can access the complete report by logging into myCigna.com. For non-Cigna members, a copy of the complete report can be obtained for a small fee by visiting the NORD website. The complete report contains additional information including symptoms, causes, affected population, related disorders, standard and investigational treatments (if available), and references from medical literature. For a full-text version of this topic, see http://www.rarediseases.org/search/rdblist.html.
The information provided in this report is not intended for diagnostic purposes. It is provided for informational purposes only. NORD recommends that affected individuals seek the advice or counsel of their own personal physicians.
It is possible that the title of this topic is not the name you selected. Please check the Synonyms listing to find the alternate name(s) and Disorder Subdivision(s) covered by this report
This disease entry is based upon medical information available through the date at the end of the topic. Since NORD's resources are limited, it is not possible to keep every entry in the Rare Disease Database completely current and accurate. Please check with the agencies listed in the Resources section for the most current information about this disorder.
For additional information and assistance about rare disorders, please contact the National Organization for Rare Disorders at P.O. Box 1968, Danbury, CT 06813-1968; phone (203) 744-0100; web site www.rarediseases.org or email email@example.com
Last Updated: 8/8/2007
Copyright 1989, 1998, 2007 National Organization for Rare Disorders, Inc.
Healthwise, Healthwise for every health decision, and the Healthwise logo are trademarks of Healthwise, Incorporated.